Print

Corporate Headquarters

150 E. Ponce de Leon Avenue
Suite 400
Decatur, GA 30030-2553
404-836-2000
consulting@oncologysolutions.com 

Resource Center

Speak with one of our professionals or learn valuable information from our resource library.

More

Oncology Solutions Industry News Feed

 
  1. FDA Approves Rituximab Plus Hyaluronidase Combination for Treatment of FL, DLBCL and CLL

    (ASCO in Action) June 22, 2017 - On June 22, 2017, the U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA, Genentech Inc.) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
  2. FDA Approves Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation

    (ASCO in Action) June 22, 2017 - On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (TAFINLAR® and MEKINIST®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC.
  3. The Closest Thing To A Shoo-In Pfizer Has Ever Handed To The FDA Just Got Rejected

    (Endpoints News) June 22, 2017 - This is the second CRL for the biosimilar.

Corporate Headquarters

150 E. Ponce de Leon Avenue
Suite 400
Decatur, GA 30030-2553
404-836-2000
consulting@oncologysolutions.com 

Resource Center

Speak with one of our professionals or learn valuable information from our resource library.

More

خرید vpn خرید کریو خرید کریو دانلود فیلم خارجی دانلود آهنگ ایرانی دانلود فیلم خرید vpn دانلود فیلم vpn خرید vpn خرید کریو Google